Rhythio Medical’s soft, conductive hydrogel technology transforms traditional defibrillation into a new class of injectable bioelectronic therapyHOUSTON--(BUSINESS WIRE)--Rhythio Medical, a medical ...

Latest analysis of U.S. real-world evidence demonstrates improved clinical outcomes when cefiderocol is used as earlier ...

Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, today announced that it will present key clinical data from HEMERA-1, its Phase 1/2 clinical trial in Acute ...

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation ...

New $25 million raise advances multi-node PI3K program; randomized phase 2 trial with Gynecologic Oncology Group Foundation now enrollingAUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, a ...

KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery.Preclinical data demonstrate deeper and durable ...

Company launches the first-of-its-kind, AI-powered clinical trial feasibility platform to accelerate clinical trial startup – ...

Funding accelerates development of novel therapeutics to improve outcomes for patients with cancerCAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--#ADC--Valink Therapeutics Inc. (“Valink”), a private ...

X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identificationWILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #CDMO--Charles River Laboratories International, ...

Steve St. Onge, PharmD, MBA promoted to Chief Business OfficerBrendan Doran, PharmD, appointed Senior Vice President of Clinical DevelopmentCOLUMBUS, Ohio--(BUSINESS WIRE)--Clarametyx Biosciences, Inc ...

SAN ANTONIO--(BUSINESS WIRE)--#BIAF--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...

Data provide insights that informed the Phase 1 study of STK-002 as a potential disease-modifying medicine for ADOA, including disease etiology, progression and clinical assessments –– ADOA is a rare ...